You are here

Ordered Arrays for Advanced Sequencing Systems

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HG004101-02A1
Agency Tracking Number: HG004101
Amount: $2,645,800.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NHGRI
Solicitation Number: PHS2010-2
Timeline
Solicitation Year: 2010
Award Year: 2010
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
INTELLIGENT BIO-SYSTEMS, INC. 34 Bear Hill Rd.
Waltham, MA -
United States
DUNS: 170777770
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 STEVEN GORDON
 (781) 466-8050
 SGORDON@INTELLIGENTBIOSYSTEMS.COM
Business Contact
Phone: (781) 466-8050
Email: sgordon@alum.mit.edu
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The advent of next-generation sequencing technologies is allowing researchers to perform studies and make discoveries which previously were not economically or technically feasible. Thus far, however, higher-throughput next-generation sequencing systems are relatively expensive, have relatively long run times and produce relatively short reads thereby limiting their use for diagnostic applications. In this Phase II application, we propose to combine the novel chip fabrication techniques developed in Phase I, the innovative sequencing by synthesis chemistry exclusively licensed from Columbia University, and an automated prototype sequencing instrument to produce an advanced sequencing by synthesis system. This system will be higher throughput and significantly more cost effective than other competing next-generation technologies. During the project, high density chips will be fabricated, the sequencing instrument and chemistry will be optimized and an E. coli genome will be re-sequenced. This system will be capable of producing large amounts of quality sequence data faster and at a lower cost than any other near-term next generation sequencing system. This will make next-generation DNA sequencing technology more accessible to the broad research community. PUBLIC HEALTH RELEVANCE: Ultimately, the ability to produce very inexpensive detailed DNA sequence information for complex organisms' genomes will both lead to accelerated discoveries throughout biology and provide the basis for Pharmacogenomics, a new paradigm in therapeutics wherein medicines are prescribed based on individual genotypes rather than just observed symptoms.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government